FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds

Improving Data Quality with Centralized Statistical Monitoring

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

Adeno-Associated Virus-Mediated Gene Therapy - Advances, Immune Challenges, and Research Innovations

FDA Modernizes Clinical Trials with Master Protocols

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Direct: Combating Rare Diseases at the FDA

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Expert Panel on Food Allergies

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA Celebrates 120 Years

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA’s Rare Disease Day 2026 – An Event for Patients

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

2025 FDA Achievements

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026